Shire To Present Additional Scientific Data On ADHD Treatment Portfolio At American Psychiatric Association Annual Meeting
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments, lisdexamfetamine dimesylate, methylphenidate transdermal system and the investigational non-stimulant treatment under FDA review, guanfacine extended release, at the American Psychiatric Association (APA) annual meeting to be held May 3rd to 8th in Washington, D.C.
Sensory Treatment Reduces Autistic Mannerisms
Parents of children with autism are increasingly turning to sensory integration treatment to help their children deal with the disorder, and they're seeing good results. In 2007, 71 percent of parents who pursued alternatives to traditional treatment used sensory integration methods, and 91 percent found these methods helpful.
Simplicity Of Working Memory Study Could Help With ADD And Other Attention Difficulties
A mind is a terrible thing to waste, but humans may have even less to work with than previously thought. University of Missouri researchers found that the average person can keep just three or four things in their "working memory" or conscious mind at one time. This finding may lead to better ways to assess and help people with attention-deficit and focus difficulties, improve classroom performance and enhance test scores.
New Analysis In Boys And Girls Shows The ADHD Patch, DAYTRANA TM , Offered ADHD Symptom Control For 12 Months
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a new data analysis that was conducted to examine treatment differences with DAYTRANA™ (methylphenidate transdermal system) between boys and girls aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD).
Shire's Investigational Nonstimulant ADHD Treatment INTUNIV TM Demonstrated Significant Efficacy In Reducing ADHD Symptoms
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, presented at a major scientific meeting findings from analyses of pivotal trial results of INTUNIV, a selective alpha-2A-agonist. This compound is an investigational once-daily medication, which is being evaluated for the treatment of the symptoms of Attention Deficit Hyperactivity Disorder (ADHD).
Attention Seeking Confused With ADHD
Teachers and parents need to beware of confusing children who are attention seeking with those who suffer from attention-deficit hyperactivity disorder (ADHD).This is the finding of Dr Nigel Mellor an independent Educational Psychologist who presented his research on Thursday 10 January 2008, at the British Psychological Society's Division of Child and Educational Psychology Annual Conference in Bournemouth.
Finding The Causes Of ADHD - New Study Launched By Norwegian Institute Of Public Health
An unprecedented ADHD study was launched on Wednesday 16th January to find causes and early warning signs of ADHD among pre-school age children. ADHD is frequently diagnosed but little is known about the causes, despite all the published research. Today there are no diagnostic criteria for ADHD in children under 6 years of age. The ADHD study intends to address many unanswered questions around the causes of this condition.
Study Raises Questions About Diagnosis, Medical Treatment Of ADHD
A new UCLA study shows that only about half of children diagnosed with attention-deficit hyperactivity disorder, or ADHD, exhibit the cognitive defects commonly associated with the condition. The study also found that in populations where medication is rarely prescribed to treat ADHD, the prevalence and symptoms of the disorder are roughly equivalent to populations in which medication is widely used.
SpeechWorks Debuts New Autism ADHD Therapy In Columbia
SpeechWorks is one of 30 providers internationally that offer the Sensory Learning Program, an innovative 30-day program geared towards correcting sensory issues in the brain. The program combines three conventional therapies into one, and it's showing progress not just for Autism, but for kids with learning disabilities, attention deficit disorder and developmental delays.
Probable Cause Identified Of Age Differences In Stimulant Response
In young children, psychostimulants relieve symptoms of Attention Deficit Disorder, yet in adolescents and adults, those same medications can cause euphoria and are often abused.What is behind these differing drug responses?Temple University scientists have identified a potential molecular mechanism, the neurotrophin system comprised of brain-derived neurotrophic factor (BDNF) and its receptor TrkB, as the cause of age differences in stimulant response.